Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Breast cancer, early stage

LBA13 - Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial


18 Sep 2020


Mini Oral - Breast cancer, early stage


Immunotherapy;  Basic Science

Tumour Site

Breast Cancer


Giampaolo Bianchini


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


G. Bianchini1, C. Huang2, D. Egle3, B. Bermejo4, C. Zamagni5, M. Thill6, A. Anton7, S. Zambelli1, S. Russo8, E.M. Ciruelos9, R. Greil10, V. Semiglazov11, M.A. Colleoni12, C.M. Kelly13, G. Mariani14, L. Del Mastro15, C. Smart16, P. Valagussa16, G. Viale17, L. Gianni16

Author affiliations

  • 1 Medical Oncology Department, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 2 Medical Oncology, National Taiwan University Hospital Taiwan Breast Cancer Consortium, Taipei/TW
  • 3 Department Of Gynecology, BrustGesundheitZentrum Tirol, Medical University Innsbruck, Innsbruck/AT
  • 4 Medical Oncology, Hospital Clinico Universitario, GEICAM Spanish Breast Cancer Group, Valencia/ES
  • 5 S.s.d. Oncologia Medica Addarii, Policlinico Sant’Orsola-Malpighi, 40138 - Bologna/IT
  • 6 Medical Oncology, Agaplesion Markus Krankenhaus, Frankfurt am Main/DE
  • 7 Medical Oncology, Hospital Universitario Miguel Servet, GEICAM Spanish Breast Cancer Group, Zaragoza/ES
  • 8 Oncologia Medica, Ospedale Santa Maria della Misericordia, Udine/IT
  • 9 Medical Oncology, University Hospital 12 De Octubre, GEICAM Spanish Breast Cancer Group, 28041 - Madrid/ES
  • 10 3rd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer; Research Institute-CCCIT, 5020 - Salzburg/AT
  • 11 Medical Oncology, NN Petrov Research Institute of Oncology, 197758 - Saint-Petersburg/RU
  • 12 Senologia Medica, IEO, Istituto Europeo di Oncologia, IRCCS, 20141 - Milano/IT
  • 13 Medical Oncology, Cancer Trials Ireland & Mater Misericordiae University Hospital, Dublin/IE
  • 14 Oncologia Medica, Istituto Nazionale dei tumori, Milano/IT
  • 15 Medical Oncology Department & Department Of Internal Medicine And Medical Specialties, University of Genova and IRCCS Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 16 Fondazione Michelangelo, Fondazione Michelangelo, 20154 - Milan/IT
  • 17 Pathology Department, IEO, Istituto Europeo di Oncologia, University of Milan, 20141 - Milano/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract LBA13


NeoTRIP, randomized 280 pts to 8 cycles of nab-paclitaxel/carbo (CT) or with atezolizumab (CT/A). 260 pts were evaluable for pCR as Per-Protocol Population.


We collected samples at baseline (n=260/260; 100%), on day 1 cycle 2 (d1c2) (n=228/260; 87.7%], and at surgery (SX) [n=231/260; 88.8%]. We assessed stromal and intratumoral TILs (sTILs, iTILs), and PD-L1 expression (SP142) on immune (IC) and tumor (TC) cells, their dynamics and association with pCR. We also aim to validate sTILs≥40% at d1c2 as predictive of pCR (Bianchini G ASCO 2020).


Baseline PD-L1 IC was balanced (IC0 43.4%; IC1 37.6%; IC2/3 18.5%), but sTILs and iTILs were higher in CT arm (p=0.046, p=0.005). All baseline biomarkers were significantly associated with pCR in CT/A, but only PD-L1 was in CT arm. Considering log PD-L1 IC (to correct skewness) as continuous variable, OR were 3.42 [1.93-6.07] (p=0.00003) and 1.51 [1.04-2.21], (p=0.032) in CT/A and CT, respectively (interaction p=0.02). pCR for CT/A vs CT (and ΔpCR) by PD-L1 IC groups were 87.0% vs 72.0% [Δ15%] (IC2/3), 56.2% vs 44.0% [Δ12.2%] (IC1) and 35.1% vs 41.1% [Δ-6.0%] (IC0). After 1 cycle of treatment (d1c2), tumor cells were not found in 28.8% (CT/A) and 13.6% (CT) (p=0.003), which was predictive of pCR (78.2% vs 42.5%, p<0.0001). TILs increased at d1c2 in both arms (p<0.0001). PD-L1 IC+ did however increase from 45.4% to 74.7% in CT/A (p=0.03) (65.8% change to pos), but decreased from 52.7% to 37.9% in CT (p=0.0001) (44.0% change to neg). In CT/A, also PD-L1 TC+ increased for 2.7% to 36.5%. In both arms, sTILs at d1c2 were more informative than baseline sTILs and ΔTILs, e.g. in CT/A, sTILs≥40% had 71.4% pCR (OR 6.38 [2.24-20.9], p=0.0007). Conversion rate of PD-L1 IC baseline to surgery (SX) was 42.9% (- to + 28.6% and + to – 14.3%) and 30.3% (- to + 9.1% and + to – 21.2%) in CT/A and CT arms, respectively.


Baseline imbalance in sTILs and iTILs might have resulted in smaller differences of pCR between arms. Atezo increased pCR by more than 10% in “immune-rich” groups (PDL1 IC+, high sTILs/iTILs). PD-L1 dynamic is strong and divergent by arm, with atezo turning most PD-L1 neg to pos. D1c2 assessment provides an early surrogate of pCR, and high rate of tumor absence may suggests that shorter therapy may be enough for some cases.

Clinical trial identification

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (NeoTRIPaPDL1) (NCT02620280).

Editorial acknowledgement

Legal entity responsible for the study

Fondazione Michelangelo.


Associazione Italiana per la Ricerca sul Cancro (AIR) (IG 2018 ID 21787), Breast Cancer Research Foundation, Roche, Celgene.


G. Bianchini: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Lilly; Advisory/Consultancy: Amgen; Advisory/Consultancy: Genomic Helath; Honoraria (self): Neopharm Israel; Advisory/Consultancy: Eisai; Advisory/Consultancy: Daiichi Sankyo; Honoraria (self): Chugai; Advisory/Consultancy: Sanofi. C-S. Huang: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Amgen; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): MSD; Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: F. Hoffman-La Roche; Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): Obi; Research grant/Funding (institution): Eirgenix. D. Egle: Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Travel/Accommodation/Expenses: Lilly; Honoraria (self), Travel/Accommodation/Expenses: MSD. C. Zamagni: Honoraria (self): Takeda; Honoraria (self): Pierre Fabre; Honoraria (self): Teva; Honoraria (self): Istituto Gentili; Advisory/Consultancy: Roche; Advisory/Consultancy: Eisai; Advisory/Consultancy: Novartis; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Pfizer; Advisory/Consultancy: PharmaMar; Advisory/Consultancy: Celgene; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Amgen; Advisory/Consultancy: Tesaro; Advisory/Consultancy: QuintilesIMS. M. Thill: Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Amgen; Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Celgene; Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Honoraria (self), Speaker Bureau/Expert testimony: MSD. E.M. Ciruelos: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis. R. Greil: Honoraria (self), Advisory/Consultancy: Celgene; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: Takeda; Honoraria (self), Advisory/Consultancy: AstaZeneca; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: Sandoz; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy: Gilead; Honoraria (self), Advisory/Consultancy: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy: Janssen; Honoraria (self), Advisory/Consultancy: MSD. M.A. Colleoni: Honoraria (self): Novartis; Advisory/Consultancy: PierreFabre; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Puma Biotechnology; Advisory/Consultancy: OBI Pharma; Advisory/Consultancy: Celldex; Advisory/Consultancy: AstraZeneca. L. Del Mastro: Honoraria (self): Roche; Honoraria (self): Pfizer; Honoraria (self): Ipsen; Honoraria (self): Eli Lilly; Honoraria (self): Novartis; Honoraria (self): Takeda; Honoraria (self): MSD; Honoraria (self): Genomic Health; Travel/Accommodation/Expenses: Celgene. G. Viale: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche Genentech; Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Travel/Accommodation/Expenses: Celgene. L. Gianni: Advisory/Consultancy: Roche; Advisory/Consultancy: Pfizer; Advisory/Consultancy: ADC Therapeutics; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Celgene; Advisory/Consultancy: GI Therapeutics; Advisory/Consultancy: Synthon; Advisory/Consultancy: Genomic Health; Advisory/Consultancy: Merk Sharp & Dome; Advisory/Consultancy: Genentech; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Odonate Therapeutics; Advisory/Consultancy: Sandoz; Advisory/Consultancy: Oncolytics Biotech; Advisory/Consultancy: Tahio Pharmaceuticals; Advisory/Consultancy, Research grant/Funding (institution): Zymeworks; Advisory/Consultancy: Genenta; Advisory/Consultancy: MetIS; Advisory/Consultancy: Novartis; Advisory/Consultancy, Research grant/Funding (institution): Revolution Medicine; Advisory/Consultancy: CD47; Advisory/Consultancy: Synaffix; Research grant/Funding (institution): Daiichi Sankyo. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.